C
Johnson & Johnson JNJ
NYSE
Recommendation
Prev Close
Volume
--
Avg Vol (90D)
Market Cap
Dividend & Yield
52-Week Range
P/E (TTM)
EPS (TTM)
C
Hold 11/7/2023Downgrade
Johnson & Johnson (JNJ) was downgraded to C from C+ on 11/7/2023 due to a decline in the volatility index and total return index.
C
Hold 8/1/2023Upgraded
Johnson & Johnson (JNJ) was upgraded to C+ from C on 8/1/2023 due to an increase in the growth index, volatility index and efficiency index. Net income increased 7,664.71% from -$68M to $5.14B, earnings per share increased from -$0.03 to $1.96, and operating cash flow increased 28.4% from $3.26B to $4.18B.
C
Hold 4/18/2023Downgrade
Johnson & Johnson (JNJ) was downgraded to C from C+ on 4/18/2023 due to a noticeable decline in the total return index, volatility index and valuation index.
C
Hold 2/28/2023Downgrade
Johnson & Johnson (JNJ) was downgraded to C+ from B- on 2/28/2023 due to a decline in the volatility index, total return index and solvency index.
B
Buy 2/17/2023Downgrade
Johnson & Johnson (JNJ) was downgraded to B- from B on 2/17/2023 due to a major decline in the growth index, volatility index and total return index. Earnings per share declined from $1.68 to $1.3195, operating cash flow declined 14.86% from $6.28B to $5.35B, and EBIT declined 10.15% from $6.6B to $5.93B.
B
Buy 2/1/2023Downgrade
Johnson & Johnson (JNJ) was downgraded to B from B+ on 2/1/2023 due to a decline in the total return index and volatility index.
B
Buy 12/21/2022Upgraded
Johnson & Johnson (JNJ) was upgraded to B+ from B on 12/21/2022 due to a large increase in the total return index.
B
Buy 9/30/2022Downgrade
Johnson & Johnson (JNJ) was downgraded to B from B+ on 9/30/2022 due to a noticeable decline in the total return index and volatility index.
B
Buy 8/1/2022Upgraded
Johnson & Johnson (JNJ) was upgraded to B+ from B on 8/1/2022 due to a large increase in the growth index, solvency index and volatility index. Operating cash flow increased 40.26% from $3.98B to $5.58B, the quick ratio increased from 1.06 to 1.09, and total revenue increased 2.54% from $23.43B to $24.02B.
B
Buy 7/28/2022Downgrade
Johnson & Johnson (JNJ) was downgraded to B from B+ on 7/28/2022 due to a decline in the total return index.
B
Buy 7/13/2022Upgraded
Johnson & Johnson (JNJ) was upgraded to B+ from B on 7/13/2022 due to an increase in the total return index and volatility index.
B
Buy 6/27/2022Downgrade
Johnson & Johnson (JNJ) was downgraded to B from B+ on 6/27/2022 due to a decline in the total return index.
B
Buy 6/9/2022Upgraded
Johnson & Johnson (JNJ) was upgraded to B+ from B on 6/9/2022 due to an increase in the total return index.
B
Buy 5/25/2022Downgrade
Johnson & Johnson (JNJ) was downgraded to B from B+ on 5/25/2022 due to a decline in the total return index.
B
Buy 5/9/2022Upgraded
Johnson & Johnson (JNJ) was upgraded to B+ from B on 5/9/2022 due to an increase in the total return index, solvency index and volatility index. Debt to equity declined from 0.46 to 0.44, and the quick ratio increased from 1.04 to 1.06.
B
Buy 2/23/2022Downgrade
Johnson & Johnson (JNJ) was downgraded to B from B+ on 2/23/2022 due to a major decline in the growth index and solvency index. Operating cash flow declined 30.86% from $8.29B to $5.73B, EBIT declined 24.59% from $6.84B to $5.16B, and the quick ratio declined from 1.05 to 1.04.
B
Buy 12/17/2021Upgraded
Johnson & Johnson (JNJ) was upgraded to B+ from B on 12/17/2021 due to an increase in the total return index and volatility index.
B
Buy 10/11/2021Downgrade
Johnson & Johnson (JNJ) was downgraded to B from B+ on 10/11/2021 due to a decline in the volatility index, total return index and growth index.
B
Buy 7/30/2021Upgraded
Johnson & Johnson (JNJ) was upgraded to B+ from B on 7/30/2021 due to a large increase in the growth index, volatility index and total return index. Operating cash flow increased 30.44% from $4.07B to $5.31B, total revenue increased 4.44% from $22.32B to $23.31B, and earnings per share increased from $2.32 to $2.35.
B
Buy 12/3/2020Upgraded
Johnson & Johnson (JNJ) was upgraded to B from B- on 12/3/2020 due to an increase in the volatility index and valuation index.
B
Buy 10/23/2020Upgraded
Johnson & Johnson (JNJ) was upgraded to B- from C+ on 10/23/2020 due to a significant increase in the growth index, valuation index and solvency index. Operating cash flow increased 142.84% from $3.45B to $8.38B, EBIT increased 43.14% from $4.17B to $5.97B, and the quick ratio increased from 0.92 to 1.17.
C
Hold 7/24/2020Downgrade
Johnson & Johnson (JNJ) was downgraded to C+ from B on 7/24/2020 due to a significant decline in the growth index, valuation index and solvency index. Earnings per share declined from $2.17 to $1.36, EBIT declined 29.76% from $5.93B to $4.17B, and total revenue declined 11.38% from $20.69B to $18.34B.
B
Buy 7/14/2020Upgraded
Johnson & Johnson (JNJ) was upgraded to B from B- on 7/14/2020 due to an increase in the total return index, valuation index and dividend index.
B
Buy 5/21/2020Downgrade
Johnson & Johnson (JNJ) was downgraded to B- from B on 5/21/2020 due to a noticeable decline in the total return index and volatility index.
B
Buy 4/23/2020Upgraded
Johnson & Johnson (JNJ) was upgraded to B from B- on 4/23/2020 due to a noticeable increase in the total return index, volatility index and solvency index.
B
Buy 4/7/2020Upgraded
Johnson & Johnson (JNJ) was upgraded to B- from C+ on 4/7/2020 due to an increase in the volatility index.
C
Hold 3/23/2020Downgrade
Johnson & Johnson (JNJ) was downgraded to C+ from B- on 3/23/2020 due to a decline in the volatility index and total return index.
B
Buy 3/20/2020Downgrade
Johnson & Johnson (JNJ) was downgraded to B- from B on 3/20/2020 due to a decline in the volatility index and growth index. EBIT declined 31.88% from $6B to $4.09B, and operating cash flow declined 15% from $7.53B to $6.4B.
B
Buy 1/6/2020Upgraded
Johnson & Johnson (JNJ) was upgraded to B from B- on 1/6/2020 due to a noticeable increase in the volatility index and total return index.
B
Buy 11/12/2019Upgraded
Johnson & Johnson (JNJ) was upgraded to B- from C+ on 11/12/2019 due to an increase in the volatility index.
C
Hold 10/8/2019Downgrade
Johnson & Johnson (JNJ) was downgraded to C+ from B- on 10/8/2019 due to a noticeable decline in the total return index and volatility index.
B
Buy 7/1/2019Downgrade
Johnson & Johnson (JNJ) was downgraded to B- from B on 7/1/2019 due to a decline in the volatility index, valuation index and dividend index.
B
Buy 6/13/2019Upgraded
Johnson & Johnson (JNJ) was upgraded to B from B- on 6/13/2019 due to an increase in the volatility index and valuation index.
B
Buy 5/29/2019Downgrade
Johnson & Johnson (JNJ) was downgraded to B- from B on 5/29/2019 due to a noticeable decline in the volatility index and valuation index.
B
Buy 2/25/2019Upgraded
Johnson & Johnson (JNJ) was upgraded to B from C on 2/25/2019 due to a significant increase in the valuation index, growth index and dividend index. Total revenue increased 0.23% from $20.35B to $20.39B.
C
Hold 2/23/2018Downgrade
Johnson & Johnson (JNJ) was downgraded to C from B on 2/23/2018 due to a significant decline in the valuation index, growth index and solvency index. Earnings per share declined from $1.37 to -$3.9901, EBIT declined 30.8% from $5.11B to $3.53B, and debt to equity increased from 0.48 to 0.57.
B
Buy 2/7/2018Downgrade
Johnson & Johnson (JNJ) was downgraded to B from B+ on 2/7/2018 due to a decline in the total return index and volatility index.
B
Buy 1/8/2018Upgraded
Johnson & Johnson (JNJ) was upgraded to B+ from B on 1/8/2018 due to a noticeable increase in the volatility index and total return index.
B
Buy 8/25/2017Downgrade
Johnson & Johnson (JNJ) was downgraded to B from B+ on 8/25/2017 due to a decline in the volatility index, total return index and valuation index.
B
Buy 4/7/2017Downgrade
Johnson & Johnson (JNJ) was downgraded to B+ from A- on 4/7/2017 due to a decline in the volatility index and valuation index.
A
Buy 3/13/2017Upgraded
Johnson & Johnson (JNJ) was upgraded to A- from B+ on 3/13/2017 due to a large increase in the total return index and volatility index.
B
Buy 2/27/2017Upgraded
Johnson & Johnson (JNJ) was upgraded to B+ from B on 2/27/2017 due to an increase in the growth index, volatility index and valuation index. Operating cash flow increased 24.1% from $5.36B to $6.65B, and total revenue increased 1.6% from $17.82B to $18.11B.
B
Buy 8/4/2016Downgrade
Johnson & Johnson (JNJ) was downgraded to B from B+ on 8/4/2016 due to a decline in the volatility index, valuation index and dividend index.
B
Buy 3/11/2016Upgraded
Johnson & Johnson (JNJ) was upgraded to B+ from B on 3/11/2016 due to an increase in the total return index, volatility index and solvency index.
B
Buy 8/20/2015Downgrade
Johnson & Johnson (JNJ) was downgraded to B from B+ on 8/20/2015 due to a decline in the volatility index, solvency index and total return index.
B
Buy 8/5/2015Upgraded
Johnson & Johnson (JNJ) was upgraded to B+ from B on 8/5/2015 due to an increase in the volatility index, solvency index and dividend index. The quick ratio increased from 1.8 to 1.87, and debt to equity declined from 0.28 to 0.27.
B
Buy 4/14/2015Downgrade
Johnson & Johnson (JNJ) was downgraded to B from B+ on 4/14/2015 due to a decline in the volatility index and total return index.
B
Buy 3/30/2015Upgraded
Johnson & Johnson (JNJ) was upgraded to B+ from B on 3/30/2015 due to an increase in the volatility index.
B
Buy 3/11/2015Downgrade
Johnson & Johnson (JNJ) was downgraded to B from B+ on 3/11/2015 due to a decline in the valuation index, solvency index and volatility index. Debt to equity increased from 0.2 to 0.27, and the quick ratio declined from 1.94 to 1.76.
B
Buy 2/20/2015Downgrade
Johnson & Johnson (JNJ) was downgraded to B+ from A- on 2/20/2015 due to a large decline in the volatility index and total return index.
A
Buy 12/12/2014Downgrade
Johnson & Johnson (JNJ) was downgraded to A- from A on 12/12/2014 due to a decline in the volatility index, growth index and solvency index. Operating cash flow declined 15.83% from $5.53B to $4.65B, EBIT declined 6.58% from $5.97B to $5.58B, and total revenue declined 5.27% from $19.5B to $18.47B.
A
Buy 10/13/2014Upgraded
Johnson & Johnson (JNJ) was upgraded to A from A- on 10/13/2014 due to an increase in the valuation index and dividend index.
A
Buy 9/26/2014Downgrade
Johnson & Johnson (JNJ) was downgraded to A- from A on 9/26/2014 due to a decline in the valuation index and dividend index.
A
Buy 8/28/2014Upgraded
Johnson & Johnson (JNJ) was upgraded to A from A- on 8/28/2014 due to a noticeable increase in the volatility index, solvency index and dividend index. Debt to equity declined from 0.23 to 0.22, and the quick ratio increased from 1.74 to 1.8.
A
Buy 7/21/2014Downgrade
Johnson & Johnson (JNJ) was downgraded to A- from A on 7/21/2014 due to a decline in the volatility index, valuation index and dividend index.
A
Buy 5/5/2014Upgraded
Johnson & Johnson (JNJ) was upgraded to A from A- on 5/5/2014 due to a major increase in the growth index, total return index and solvency index. EBIT increased 38.65% from $4.07B to $5.65B, earnings per share increased from $1.2253 to $1.64, and the quick ratio increased from 1.59 to 1.74.
Weiss Ratings